SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNationwide Ccds Regulatory News (NBS)

Share Price Information for Nationwide Ccds (NBS)

Share Price is delayed by 15 minutes
Get Live Data
129.00    0.00 (0.00%)
Bid:
127.00
Ask:
131.00
Spread: 4.00 (3.15%)
Market Cap: £1.18b
NBS Live PriceLast checked at - London Stock Exchange

Intraday Nationwide Ccds Share Chart

Stabilisation Notice

3 Jun 2025 09:21

RNS Number : 2102L
J.P. Morgan Securities PLC.
03 June 2025
 

3rd June 2025

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

Nationwide Building Society Pre-stabilisation Period Announcement

J.P. Morgan Securities plc, (contact: Robert Chambers +442071342468) hereby gives notice, as Stabilisation Coordinator, that the Stabilising Manager(s) named below may stabilise the offer of the following securities in accordance with Commission Delegated Regulation EU/xxx/2016 under the Market Abuse Regulation (EU/596/2016).

The securities:

Issuer:

Nationwide Building Society

Guarantor (if any):

N/A

Aggregate nominal amount:

GBP Benchmark

Description:

GBP PNC Dec 31

Direct, unsecured and subordinated AT1 notes

Listing: London Stock Exchange

Offer price:

TBC

Other offer terms:

GBP 200k x 1k

Stabilisation: Relevant Stabilisation regulation applies 

Stabilisation Manager(s):

J.P. Morgan Securities Plc (Stabilisation coordinator)

Natwest (Stabilisation manager)

Lloyds (Stabilisation manager)

Stabilisation period expected to start on:

3rd June 2025

Stabilisation period expected to end no later than:

3rd July 2025

 

Existence, maximum size and conditions of use of overallotment facility:

The Stabilisation Manager(s) may over-allot the securities in an amount not exceeding 5% of the aggregate nominal amount stated above.

Stabilisation trading venue:

Over the counter, TBC

 

In connection with the offer of the above securities, the Stabilising Manager(s), or persons acting on behalf of the Stabilising Manager(s) may over-allot the securities, provided that the aggregate principal amount of the securities allotted does not exceed 105 percent of the aggregate principal amount of the securities, or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, stabilisation may not necessarily occur and any stabilisation action, if begun, may cease at any time, but it must end no later than the earlier of 30 days after the issue date of the securities and 60 days after the date of allotment of the securities.

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

This announcement and the offer of the securities to which it relates are only addressed to and directed at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within Article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that in that Member State

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STAEAPKDEFNSEEA
Date   Source Headline
12th Jun 20262:02 pmRNSPublication of a Prospectus
12th Jun 202611:31 amRNSPublication of Registration Document
12th Jun 202611:24 amRNSPublication of a Prospectus
9th Jun 202611:15 amRNSAdmission to Trading
8th Jun 202611:52 amRNSNOTICE TO NOTEHOLDERS
5th Jun 20262:58 pmRNSPublication of Final Terms
21st May 202612:33 pmRNSPublication of a Supplementary Prospectus
21st May 20267:00 amRNSPreliminary Results Announcement
6th May 20263:12 pmRNSPublication of Final Terms
21st Apr 20263:38 pmRNSPublication of Final Terms
21st Apr 202610:20 amRNSCancellation of Listing
20th Apr 202612:38 pmRNSNotice to Covered Bondholders
9th Apr 202611:06 amRNSPublication of a Supplementary Prospectus
7th Apr 20267:00 amRNSPart VII Transfer & Board changes
20th Mar 20268:48 amRNSRedemption of Securities
3rd Mar 202611:50 amRNSAdmission to Trading
3rd Mar 202611:44 amRNSAdmission to Trading
27th Feb 20265:18 pmRNSPublication of Final Terms
27th Feb 20263:56 pmRNSPublication of Final Terms
26th Feb 202611:00 amRNSPart VII Transfer
24th Feb 20269:51 amRNSAdmission to Trading
20th Feb 20269:47 amRNSPublication of Final Terms
19th Feb 202610:04 amRNSAdmission to Trading
17th Feb 20269:56 amRNSAdmission to Trading
17th Feb 20269:46 amRNSPublication of Final Terms
13th Feb 20262:04 pmRNSPublication of Final Terms
13th Feb 20268:15 amRNSPost Stabilisation Notice
3rd Feb 20262:41 pmRNSAdmission to Trading
30th Jan 20261:00 pmRNSPublication of Final Terms
16th Jan 20261:21 pmRNSPublication of Final Terms
8th Jan 20261:49 pmRNSPublication of Final Terms
8th Jan 20267:00 amRNSDirectorate change
7th Jan 202610:49 amRNSPre Stabilisation Notice
19th Dec 202511:00 amRNSDirectorate change
19th Dec 202511:00 amRNSDirectorate change
16th Dec 20252:42 pmRNSPublication of a Supplementary Prospectus
2nd Dec 20257:10 amRNSResponse to 2025 BOE Capital Stress Test Results
2nd Dec 20257:00 amRNSRevocation of Sub-consolidation Direction
20th Nov 202511:47 amRNSPublication of Supplement
20th Nov 20257:00 amRNSInterim Results September 2025
14th Nov 202511:00 amRNSPart VII Transfer
21st Oct 20251:08 pmRNSPublication of Final Terms
10th Oct 202512:52 pmRNSPublication of Final Terms
1st Oct 20257:00 amRNSConfirmation of Post-Offer Intention Statements
30th Sep 202510:03 amRNSBoard Changes
30th Sep 20259:43 amRNSBoard Changes
30th Sep 20257:00 amRNSBoard Changes
26th Sep 20252:49 pmRNSPublication of Final Terms
16th Sep 20251:48 pmRNSPublication of Final Terms
8th Sep 202511:27 amRNSPublication of Final Terms

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.